Case Studies| Volume 13, ISSUE 3, P402-404, May 2019

High Lp(a) associated with very premature coronary heart disease

Published:March 20, 2019DOI:


      • Premature coronary heart disease (CHD) is uncommon in young women.
      • Common causes of premature CHD include familial hypercholesterolemia, diabetes, and heavy smoking.
      • This case adds high lipoprotein(a) levels as another potential cause of premature CHD.


      Although high levels of Lp(a) have become increasingly recognized as a risk factor for coronary heart disease (CHD), its association with very premature CHD (ie, younger than 30 years) is unclear. We present a case of a young woman with very high levels of Lp(a) in whom accelerated CHD is unlikely to be accounted for by traditional risk factors.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lakshminarayan D.
        • Elajami T.K.
        • Devabhaktuni S.
        • Welty F.K.
        Ischemic stroke in a young adult with extremely elevated lipoprotein(a): a case report and review of literature.
        J Clin Lipidol. 2016; 10: 1266-1271
        • Yang W.X.
        • Yang Z.
        • Wu Y.J.
        • Qiao S.B.
        • Yang Y.J.
        • Chen J.L.
        Factors associated with coronary artery disease in young population (age ≤ 40): analysis with 217 cases.
        Med Sci J. 2014; 1: 38-42
        • Arsenault B.J.
        • Barter P.
        • DeMicco D.A.
        • et al.
        • Treating to New Targets (TNT) Investigators
        Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers.
        PLoS One. 2014; 9: e114519
        • Tselepis A.D.
        Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role.
        J Biomed Res. 2018; 32: 13-22
        • Tsimikas S.
        A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.
        J Am Coll Cardiol. 2017; 69: 692-711
        • van Dijk R.A.
        • Kolodgie F.
        • Ravandi A.
        • et al.
        Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions.
        J Lipid Res. 2012; 53: 2773-2790
        • Kamstrup P.R.
        • Benn M.
        • Tybjærg-Hansen A.
        • Nordestgaard B.G.
        Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the copenhagen city heart study.
        Circulation. 2008; 117: 176-184
        • Weinberger I.
        • Rotenberg Z.
        • Fuchs J.
        • Sagy A.
        • Friedmann J.
        • Agmon J.
        Myocardial infarction in young adults under 30 years: risk factors and clinical course.
        Clin Cardiol. 1987; 10: 9-15
        • Doughty M.
        • Mehta R.
        • Bruckman D.
        • et al.
        Acute myocardial infarction in the young--The University of Michigan experience.
        Am Heart J. 2002; 143: 56-62
        • McCready R.A.
        • Vincent A.E.
        • Schwartz R.W.
        • Hyde G.L.
        • Mattingly S.S.
        • Griffen Jr., W.O.
        Atherosclerosis in the young: a virulent disease.
        Surgery. 1984; 96: 863-869
        • Leebmann J.
        • Roeseler E.
        • Julius U.
        • et al.
        Pro(a)LiFe Study Group*. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
        Circulation. 2013; 128: 2567-2576
        • Heigl F.
        • Hettich R.
        • Lotz N.
        • et al.
        Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany.
        Atheroscler Suppl. 2015; 18: 154-162
        • Raal F.J.
        • Giugliano R.P.
        • Sabatine M.S.
        • et al.
        PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
        J Lipid Res. 2016; 57: 1086-1096
        • Tsimikas S.
        Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
        Curr Opin Endocrinol Diabetes Obes. 2016; 23: 157-164